Cargando…
In Vivo Emergence of a Novel Protease Inhibitor Resistance Signature in HIV-1 Matrix
Protease inhibitors (PIs) are the second- and last-line therapy for the majority of HIV-infected patients worldwide. Only around 20% of individuals who fail PI regimens develop major resistance mutations in protease. We sought to explore the role of mutations in gag-pro genotypic and phenotypic chan...
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Society for Microbiology
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7642677/ https://www.ncbi.nlm.nih.gov/pubmed/33144375 http://dx.doi.org/10.1128/mBio.02036-20 |